Table 4 Validation of Calculated Hasford and Sokal Scores
| Â | 3-mo CHR, all treatments (n = 35) | 3-mo CHR, imatinib only (n = 32) | ||||
|---|---|---|---|---|---|---|
| Â | Yes | No | P Value | Yes | No | P Value |
Hasford Score | Â | Â | 0.035 | Â | Â | 0.0454 |
   </=780 low-risk | 17 (85%) | 3 (15%) |  | 16 (88.9%) | 2 (11.1%) |  |
   >780 and </=1480 intermediate | 5 (41.7%) | 7 (58.3%) |  | 5 (45.5%) | 6 (55.5%) |  |
   >1480 high-risk | 2 (66.7%) | 1 (33.3%) |  | 2 (66.7%) | 1 (33.3%) |  |
Sokal Score | Â | Â | 0.015 | Â | Â | 0.0043 |
   <0.8 good prognosis | 14 (93.3%) | 1 (6.7%) |  | 13 (100%) | 0 (0%) |  |
   0.8–1.2 moderate prognosis | 7 (58.3%) | 5 (41.7%) |  | 7 (58.3%) | 5 (41.7%) |  |
   >1.2 poor prognosis | 3 (37.5%) | 5 (62.5%) |  | 3 (42.9%) | 4 (57.1%) |  |